Corient Private Wealth LP Decreases Stock Position in Astrazeneca Plc $AZN

Corient Private Wealth LP trimmed its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 7.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,104 shares of the company’s stock after selling 7,636 shares during the quarter. Corient Private Wealth LP’s holdings in Astrazeneca were worth $18,401,000 at the end of the most recent quarter.
• The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Other hedge funds also recently bought and sold shares of the company. Amundi raised its holdings in Astrazeneca by 146,574.4% in the first quarter. Amundi now owns 15,386,149 shares of the company’s stock valued at $3,034,456,000 after acquiring an additional 15,375,659 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Astrazeneca by 889.9% in the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after purchasing an additional 10,742,268 shares during the last quarter. Rathbones Group PLC lifted its position in shares of Astrazeneca by 106,772.0% during the 1st quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock worth $1,560,419,000 after purchasing an additional 8,047,406 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Astrazeneca by 208.6% during the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after purchasing an additional 7,021,126 shares during the last quarter. Finally, Swiss National Bank acquired a new position in shares of Astrazeneca during the first quarter worth $1,202,714,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Shares of Astrazeneca stock opened at $163.75 on Tuesday. The company has a market capitalization of $253.97 billion, a P/E ratio of 24.48, a PEG ratio of 1.36 and a beta of 0.25. Astrazeneca Plc has a 1 year low of $145.79 and a 1 year high of $212.71. The company’s fifty day moving average is $165.58 and its two-hundred day moving average is $181.86. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.
• As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The company had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same quarter in the prior year, the firm earned $2.17 EPS. Astrazeneca’s quarterly revenue was up 6.4% on a year-over-year basis. Analysts forecast that Astrazeneca Plc will post 9.34 earnings per share for the current year.

Here are the key news stories impacting Astrazeneca this week:
• Eight-year follow-up from the Phase 3 ADAURA trial showed that adjuvant Tagrisso reduced the risk of death by 47% in the primary patient population and 48% across the overall group with early-stage EGFR-mutated lung cancer. The durable survival benefit supports Tagrisso’s position in AstraZeneca’s oncology portfolio and may strengthen expectations for continued sales.
• Analyst earnings estimates for fiscal 2026 were reportedly raised, indicating improved expectations for AstraZeneca’s future profitability.
• Separate coverage highlighted mixed oncology results: strong long-term survival outcomes in lung cancer were accompanied by weaker data in advanced breast cancer, leaving the overall clinical readout uneven.
• Etcamah failed to significantly improve progression-free survival in the Phase 3 SERENA-4 trial for first-line advanced breast cancer. Although the result does not affect its existing approved use, it limits the drug’s potential expansion and creates a setback for AstraZeneca’s breast-cancer pipeline.
• The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

AZN has been the topic of a number of analyst reports. Weiss Ratings cut Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. CICC Research initiated coverage on Astrazeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 target price on the stock. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average target price of $206.67.

Get Our Latest Research Report on Astrazeneca

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.
• Five stocks we like better than Astrazeneca
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Astrazeneca Right Now?

Before you consider Astrazeneca, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Astrazeneca wasn’t on the list.

While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here…Read more by MarketBeat